1. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999–2000. JAMA 2002;288(14):1723–1727.
2. World Health Organization. Obesity: preventing and managing the global epidemic. WHO Technical Report Series 894. Geneva: World Health Organization, 2000.
3. Mokdad A, Ford E, Bowman B, et al. Diabetes trends in the U.S. Diabetes Care 2000;23:1278–1283.
4. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287(3):356–359.
5. Pi-Sunyer FX. Medical hazards of obesity. Ann Intern Med 1993; 119:655–660.
6. Kissebah A, Peiris AN, Evans D. Mechanisms associating body fat distribution to glucose intolerance and diabetes mellitus: window with a view. Acta Med Scand 1988;723(suppl):79–89.
7. Després JP. Lipoprotein metabolism in visceral obesity. Int J Obes 1991;15(suppl 2):45–52.
8. Ohlson LO, Larsson B, Svärdsudd K, et al. The influence of body fat distribution on the incidence of diabetes mellitus: 13.5 years of follow up of the participants in the study of men born in 1913. Diabetes 1985;34:1055–1058.
9. Lapidus L, Bengtsson C, Larsson B, et al. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. BMJ 1984;289:1257–1261.
10. Larsson B, Svardsudd K, Welin L, et al. Abdominal adipose tissue distribution, obesity and risk of cardiovascular disease and death: 13-year follow up of participants in the Study of Men Born in 1913. BMJ 1984;288:1401–1404.
11. Haffner SM, Mitchell BD, Hazuda HP, et al. Greater influence of central distribution of adipose tissue on incidence of non–insulin-dependent diabetes in women than men. Am J Clin Nutr 1991;53: 1312–1317.
12. Allison DB, Pi-Sunyer FX. Obesity treatment: examining the premises. Endo Prac 1995;1(5):353–364.
13. National Heart Lung and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the evidence report. Obes Res 1998;6(suppl 2): 51–210.
14. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343–1350.
15. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403.
16. National Heart Lung and Blood Institute. The practical guide, identification, evaluation, and treatment of overweight and obesity in adults. Bethesda, MD: National Institutes of Health, 2000.
17. Zumoff B, Strain G, Miller L. Plasma free and non–sex-hormone-binding-globulin-testosterone are decreased in obese men in proportion to their degree of obesity. J Clin Endocrinol Metab 1990;70: 929–931.
18. World Health Organization, International Association for the Study of Obesity, International Obesity Task Force. The Asia-Pacific perspective: redefining obesity and its treatment. Health Communications Australia, 2000.
19. Lemieux S, Prud’homme D, Bouchard C, et al. A single threshold value of waist girth to identify non-obese and overweight subjects with excess visceral adipose tissue. Am J Clin Nutr 1996;64:685–693.
20. Williamson DF, Pamuk E, Thun M, et al. Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40–64 years. Am J Epidemiol 1995;141(12): 1128–1141.
21. Pi-Sunyer FX. Short-term medical benefits and adverse effects of weight loss. Ann Intern Med 1993;119:722–726.
22. Hughes TA, Gwynne JT, Switzer BR, et al. Effects of caloric restriction and weight loss on glycemic control, insulin release and resistance, and atherosclerotic risk in obese patients with type II diabetes mellitus. Am J Med 1984;77:7–17.
23. Bitzen P-O, Melander A, Schersten B, et al. Efficacy of dietary regulation in primary health care patients with hyperglycaemia detected by screening. Diabet Med 1988;5:640–647.
24. Carpenter M, Bodansky H. Drug treatment of obesity in type 2 diabetes mellitus. Diabet Med 1990;7:99–104.
25. Henry RR, Wiest-Kent TA, Scheaffer L, et al. Metabolic consequences of very-low-calorie diet therapy in obese non–insulin-dependent diabetic and non-diabetic subjects. Diabetes 1986;35:155–164.
26. Henry R, Wallace P, Olefsky JM. Effects of weight loss on mechanisms of hyperglycemia in obese non–insulin-dependent diabetes mellitus. Diabetes 1986;35:990–998.
27. Henry R, Gumbiner B. Benefits and limitations of very-low-calorie diet therapy in obese NIDDM. Diabetes Care 1991;14:802–823.
28. Wing RR, Koeske R, Epstein L, et al. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 1987; 147:1749–1753.
29. Pi-Sunyer FX. A review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity. Clin Ther 1996;18(6):1006–1035.
30. UKPDS Group. UK Prospective Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients. Metabolism 1990;39(9):905–912.
31. Watts NB, Spanheimer RG, DiGirolamo M, et al. Prediction of glucose response to weight loss in patients with non–insulin-dependent diabetes mellitus. Arch Intern Med 1990;150:803–806.
32. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537–544.
33. Schotte D, Stunkard AJ. The effect of weight reduction on blood pressure in 301 obese patients [Abstract]. Arch Intern Med 1990;150: 1701–1704.
34. Kanders B, Blackburn GL, Lavin P, et al. Weight loss outcome and health benefits associated with the Optifast program in the treatment of obesity. Int J Obes 1898;13(suppl 2):131–134.
35. Mancini M, Di Biase G, Contaldo F, et al. Medical complication of severe obesity: importance of treatment by very-low-calorie diets: intermediate and long-term effects. Int J Obes 1981;5:341–352.
36. Foley EF, Benotti PN, Borlase BC, et al. Impact of gastric restrictive surgery on hypertension in the morbidly obese. Am J Surg 1992; 163:294–297.
37. Bagdade J, Bierman EL, Porte D. The significance of basal insulin levels in the evaluation of the insulin response to glucose in diabetic and nondiabetic subjects. J Clin Invest 1967;46:1549–1557.
38. Higgins M, D’Agostino RB, Kannel W, et al. Benefits and adverse effects of weight loss: observations from the Framingham Study. Ann Intern Med 1993;119:758–763.
39. Langford HG, Blaufox MD, Oberman A, et al. Dietary therapy slows the return of hypertension after stopping prolonged medication. JAMA 1985;253:657–664.
40. Stamler R, Stamler J, Grimm RH Jr, et al. Nutritional therapy for high blood pressure: final report of a four-year randomized clinical trial—the Hypertension Control Program. JAMA 1987;257:1484–1491.
41. Stevens VJ, Corrigan SA, Obarzanek E, et al. Weight loss intervention in phase 1 of the Trials of Hypertension Prevention: the TOHP Collaborative Research Group. Arch Intern Med 1993;153:849–858.
42. Ramsay LE, Ramsay MH, Hettiarachchi J, et al. Weight reduction in a blood pressure clinic. BMJ 1978;2:244–245.
43. Heyden S, Borhani NO, Tyroler HA, et al. The relationship of weight change to changes in blood pressure, serum uric acid, cholesterol and glucose in the treatment of hypertension. J Chronic Dis 1985;38:281–288.
44. Davis BR, Blaufox M, Oberman A, et al. Reduction in long-term antihypertensive medication requirements: effects of weight reduction by dietary intervention in overweight persons with mild hypertension. Arch Intern Med 1993;153:1773–1782.
45. Joint National Committee. The sixth report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Arch Intern Med 1997;157:2413–2446.
46. Després JP, Moorjani S, Lupien PJ, et al. Regional distribution of body fat, plasma lipoproteins, cardiovascular disease. Arteriosclerosis 1990;10:497–511.
47. Kraus RM. Triglycerides and atherogenic lipoproteins: rationale for lipid management. Am J Med 1998;105(suppl):58–62.
48. Follick M, Abrams D, Smith T, et al. Contrasting short- and long-term effects of weight loss on lipoprotein levels. Arch Intern Med 1984;144:1571–1574.
49. Carmena R, Ascaso J, Tebar J, et al. Changes in plasma high-density lipoproteins after body weight reduction in obese women. Int J Obes 1984;8:135–140.
50. Fachnie J, Foreback C. Effects of weight reduction, exercise and diet modification on lipids and apolipoproteins A-1 and B in severely obese persons. Henry Ford Hosp Med J 1987;35:216–220.
51. Schieffer B, Moore D, Funke E, et al. Reduction of atherogenic risk factors by short-term weight reduction: evidence of the efficacy of National Cholesterol Education Program guidelines for the obese. Klin Wochenschr 1991;69:163–167.
52. Wylie-Rosett J, Swencionis C, Peters MH, et al. A weight reduction intervention that optimizes use of practitioner’s time, lowers glucose level, and raises HDL cholesterol level in older adults. J Am Diet Assoc 1994;94:37–42.
53. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 1999;22(suppl 1):56–59.
54. Hall Y, Stamler J, Cohen DB, et al. Effectiveness of a low saturated fat, low cholesterol, weight-reducing diet for the control of hypertriglyceridemia. Atherosclerosis 1972;16:389–403.
55. Wood PD, Stefanick ML, Dreon DM, et al. Changes in plasma lipids and lipoproteins in overweight men during weight loss through dieting as compared with exercise. N Engl J Med 1988;319: 1173–1179.
56. Brolin RE, Kenler HA, Wilson AC, et al. Serum lipids after gastric bypass surgery for morbid obesity. Int J Obes 1990;14:939–950.
57. Weintraub M, Sundaresan P, Schuster B. Long-term weight control study VII (weeks 0–210). Clin Pharmacol Ther 1992;51:634–641.
58. Singh RB, Dubnov G, Niaz MA, et al. Effect of an Indo-Mediterranean diet on progression of coronary artery disease in high risk patients (Indo-Mediterranean Diet Heart Study): a randomised single-blind trial. Lancet 2002;360(9344):1455–1461.
59. de Lorgeril M, Salen P, Martin JL, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999;99(6):779–785.
60. Peiser J, Lavie P, Ovnat A, et al. Sleep apnea syndrome in the morbidly obese as an indication for weight reduction surgery. Ann Surg 1984;199:112–115.
61. Charuzi I, Ovnat A, Peiser J, et al. The effects of surgical weight reduction on sleep quality in obesity-related sleep apnea syndrome. Surgery 1985;97:535–538.
62. Pons J-B, Montanari A. Eficacia de la perdida de peso en el tratamiento del sindrome de apneas obstructivas durante el sueño: experiencia en 135 pacientes. Med Clin (Barc) 1992;98:45–48.
63. Aubert G. Alternative therapeutic approaches in sleep apnea syndrome. Sleep 1992;15(suppl):69–72.
64. Pasquali R, Colella P, Cirignotta F, et al. Treatment of obese patients with obstructive sleep apnea syndrome (OSAS): effect of weight loss and interference of otorhinolaringoiatric pathology. Int J Obes 1990;14:207–217.
65. Rajala R, Partinen M, Sane T, et al. Obstructive sleep apnoea syndrome in morbidly obese patients. J Intern Med 1991;230:125–129.
66. Schlierf G, Schellenberg B, Stiehl A, et al. Biliary cholesterol saturation and weight reduction—effects of fasting and low-calorie diet. Digestion 1981;21:44–49.
67. Reuben A, Quershi Y, Murphy G, et al. Effect of obesity and weight reduction on biliary cholesterol saturation and the response to chenodeoxycholic acid. Eur J Clin Invest 1985;16:133–142.
68. Heshka S, Spitz A, Nunez C, et al. Obesity and risk of gallstone development on a 1200 kcal/d (5025 Kj/d) regular food diet. Int J Obes Rel Metab Disord 1996;20(5):450–454.
69. Maclure KM, Hayes KC, Colditz GA, et al. Weight, diet, and the risk of symptomatic gallstones in middle-aged women. N Engl J Med 1989;321(9):563–569.
70. Foster G, Wadden T, Vogt R, et al. What is a reasonable weight loss? Patients’ expectations and evaluations of obesity treatment outcomes. J Consult Clin Psychol 1997;65:79–85.
71. Blackburn GL. Effect of degree of weight loss on health benefits. Obes Res 1995;3(suppl 2):211–216.
72. Committee to Develop Criteria for Evaluating the Outcomes of Approaches to Prevent and Treat Obesity, I. M. Weighing the options: criteria for evaluating weight-management programs. In: Thomas PR, ed. Washington, DC: National Academy Press, 1995.
73. Pi-Sunyer FX. The role of very-low-calorie diets in obesity. Am J Clin Nutr 1992;56(suppl):240–243.
74. Lichtman SW, Pisarska K, Berman ER, et al. Discrepancy between self-reported and actual caloric intake and exercise in obese subjects. N Engl J Med 1992;327(27):1893–1898.
75. Yang MU, Van Itallie TB. Effect of energy restriction on body composition and nitrogen balance in obese individuals: treatment of the seriously obese patient. New York: Guilford Press, 1992:83–106.
76. De Lorenzo A, Petroni ML, De Luca PP, et al. Use of quality control indices in moderately hypocaloric Mediterranean diet for treatment of obesity. Diabetes Nutr Metab 2001;14(4):181–188.
77. Atkins RC. Dr. Atkins’ new diet revolution. New York: Avon, 2001.
78. Westman EC, Yancy WS, Edman JS, et al. Effect of 6-month adherence to a very low carbohydrate diet program. Am J Med 2002;113 (1):30–36.
79. St. Jeor ST, Howard BV, Prewitt TE, et al. Dietary protein and weight reduction: a statement for healthcare professionals from the Nutrition Committee of the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Association. Circulation 2001; 104(15):1869–1874.
80. Ornish D, Scherwitz LW, Billings JH, et al. Intensive lifestyle changes for reversal of coronary heart disease. JAMA 1998;280(23): 2001–2007.
81. Pritikin R. The Pritikin principle. Alexandria, VA: Time Life Books, 2000.
82. Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990; 336(8708):129–133.
83. Foster GD, Watt HR, Hill JO, et al. Evaluation of the Atkins diet: a randomized controlled trial (RCT) [Abstract]. Obes Res Suppl 2001; 3:85.
84. U.S. Department of Agriculture and U.S. Department of Health and Human Services. Dietary guidelines for Americans. Home and garden bulletin no. 232. Washington, DC: U.S. Government Printing Office, 1995.
85. Malmberg K, Yusuf S, Gerstein HC, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non–Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000;102(9):1014–1019.
86. Reddy ST, Wang CY, Sakhaee K, et al. Effect of low-carbohydrate high-protein diets on acid-base balance, stone-forming propensity, and calcium metabolism. Am J Kidney Dis 2002;40(2):265–274.
87. Ditschuneit HH, Flechtner-Mors M, Johnson TD, et al. Metabolic and weight-loss effects of a long-term dietary intervention in obese patients. Am J Clin Nutr 1999;69(2):198–204.
88. Flechtner-Mors M, Ditschuneit HH, Johnson TD, et al. Metabolic and weight loss effects of long-term dietary intervention in obese patients: four-year results. Obes Res 2000;8(5):399–402.
89. Nonas CA, Pi-Sunyer FX. Obesity. In: Morrison G, Hark L, eds. Medical nutrition and disease. Malden, MA: Blackwell Science, 1999.
90. Van Itallie T, Yang M. Current concepts in nutrition: diet and weight loss. N Engl J Med 1977;297:1158–1161.
91. Albu J, Smolowitz J, Lichtman S, et al. Composition of weight loss in severely obese women: a new look at old methods. Metabolism 1992;41:1068–1074.
92. Hendel HW, Gotfredsen A, Andersen T, et al. Body composition during weight loss in obese patients estimated by dual energy X-ray absorptiometry and by total body potassium. Int J Obes Rel Metab Disord 1996;20(12):1111–1119.
93. Johnston PK. Vegetarian nutrition: proceedings of a symposium held in Arlington, VA. Am J Clin Nutr 1994;59(suppl):1099–1262.
94. Blair SN, Kohl HW, Barlow CE. Physical activity, physical fitness, and all-cause mortality in women: do women need to be active? J Am Coll Nutr 1993;12(4):368–371.
95. Helmrich S, Ragland D, Leung R, et al. Physical activity and reduced occurrence of non–insulin-dependent diabetes mellitus. N Engl J Med 1991;325:147–152.
96. Haapanen N, Millunpalo I, Vuori P, et al. Association of leisure time physical activity with the risk of CHD. Int J Epidemiol 1997;26: 739–747.
97. Hsieh S, Yoshinaga H, Muto T, et al. Regular physical activity and coronary risk factors in Japanese men. Circulation 1998;97:661–665.
98. Barlow C, Kohl H III, Gibbons L, et al. Physical fitness, mortality and obesity. Int J Obes Rel Metab Disord 1995;19(suppl):41–44.
99. Lee C, Blair S, Jackson A. Cardiorespiratory fitness, body composition, and all-cause and cardiovascular disease mortality in men. Am J Clin Nutr 1999;69:373–380.
100. Lee C, Jackson A, Blair S. US weight guidelines: is it also important to consider cardiorespiratory fitness? Int J Obes Rel Metab Disord 1998;22(suppl):2–7.
101. Kelley DE, Goodpaster BH. Effects of physical activity on insulin action and glucose tolerance in obesity. Med Sci Sports Exerc 1999;31(suppl):619–623.
102. DeFronzo RA, Sherwin RS, Kraemer N. Effect of physical training on insulin action in obesity. Diabetes 1987;36(12):1379–1385.
103. Kang J, Robertson RJ, Hagberg JM, et al. Effect of exercise intensity on glucose and insulin metabolism in obese individuals and obese NIDDM patients. Diabetes Care 1996;19:341–349.
104. Smutok MA, Reece C, Kokkinos PF, et al. Effects of exercise training modality on glucose tolerance in men with abnormal glucose regulation. Int J Sports Med 1994;15:283–289.
105. James S, Jamjoum L, Raghunathan T, et al. Physical activity and NIDDM in African-Americans: the Pitt County Study. Diabetes Care 1998;21:555–562.
106. Manson JE, Nathan DM, Krowleski A, et al. A prospective study of exercise and incidence of diabetes among U.S. male physicians. JAMA 1992;268:63–67.
107. Manson JE, Rimm EB, Stampfer MJ, et al. Physical activity and incidence of non–insulin dependent diabetes mellitus in women. Lancet 1991;338:774–778.
108. Pan D, Lillioja S, Kriketos A, et al. Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes 1997;46:983–988.
109. Perry IJ, Wannamethee SG, Walker MK, et al. Prospective study of risk factors for development of non–insulin dependent diabetes in middle aged British men. BMJ 1995;310:560–564.
110. Fagard R. Physical activity in the prevention and treatment of hypertension in the obese. Med Sci Sports Exerc 1999;31(suppl):624–630.
111. Stefanick ML, Mackey S, Sheehan M, et al. Effects on diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of low density lipoprotein (LDL) cholesterol. N Engl J Med 1998;339:12–20.
112. Wing RR. Physical activity in the treatment of the adulthood overweight and obesity: current evidence and research issues. Med Sci Sports Exerc 1999;31(suppl):547–552.
113. Pavlou KN, Krey S, Steffee WP. Exercise as an adjunct to weight loss and maintenance in moderately obese subjects. Am J Clin Nutr 1989;49(5 suppl):1115–1123.
114. Wadden TA, Vogt R, Andersen R, et al. Exercise in the treatment of obesity: effects of four interventions on body composition, resting energy expenditure, and mood. J Consult Clin Psychol 1997;65:269–277.
115. Pronk N, Wing RR. Physical activity and long-term maintenance of weight loss. Obes Res 1994;2:587–599.
116. Miller W, Koceja D, Hamilton E. A meta-analysis of the past 25 years of weight loss research using diet, exercise or diet plus exercise intervention. Int J Obes 1997;21:941–947.
117. Schoeller D, Shay K, Kushner RF. How much physical activity is needed to minimize weight gain in previously obese women? Am J Clin Nutr 1997;66:551–556.
118. Klem M, Wing RR, McGuire M, et al. A descriptive study of individuals successful at long-term maintenance of substantial weight loss. Am J Clin Nutr 1997;66:239–246.
119. Gutin B, Kessler G. The high energy factor. New York: Random House, 1983.
120. Weigle DS, Brunzell JD. Assessment of energy expenditure in ambulatory reduced-obese subjects by the techniques of weight stabilization and exogenous weight replacement. Int J Obes 1990;14:69–77.
121. Harris JK, French SA, Jeffrey RW, et al. Dietary and physical activity correlates of long-term weight loss. Obes Res 1994;2:307–313.
122. Kayman S, Bruvold W, Stern JS. Maintenance and relapse after weight loss in women: behavioral aspects. Am J Clin Nutr 1990;52 (5):800–807.
123. McGuire MT, Wing RR, Klem ML, et al. What predicts weight regain in a group of successful weight losers? J Consult Clin Psychol 1999;67:177–185.
124. Bouchard C, Perusse L, Leblanc C, et al. Inheritance of the amount and distribution of human body fat. Int J Obes 1988;12:205–215.
125. Bouchard C, Tremblay A, Després JP, et al. The response to long-term overfeeding in identical twins. N Engl J Med 1990;24:1477–1482.
126. Stunkard AJ, Sorensen TI, Hanis C, et al. An adoption study of human obesity. N Engl J Med 1986;314:193–198.
127. Wadden TA, Berkowitz R, Sarwer D, et al. Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial. Arch Intern Med 2001;161:218–227.
128. Bray GA, Blackburn GL, Ferguson JM, et al. Sibutramine produces dose-related weight loss. Obes Res 1999;7:189–198.
129. Meridia Package Insert, revised, 2001.
130. Fanghanel G, Cortinas L, Sanchez-Reyes L, et al. A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity. Int J Obes Rel Metab Disord 2000;24:144–150.
131. Fujioka K, Seaton TB, Rowe E, et al. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Sibutramine/Diabetes Clinical Study Group. Diabetes Obes Metab 2000;2:175–187.
132. Finer N, Bloom S, Frost G, et al. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double blind, placebo-controlled study. Diabetes Obes Metab 2000; 2:105–112.
133. James WPT, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trail. STORM study group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000;356:2119–2125.
134. Anonymous. Sibutramine for obesity. Med Lett Drugs Ther 1998; 40:32.
135. McMahon F, Fujioka K, Singh B, et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year double-blind, placebo-controlled, multicenter trial. Arch Intern Med 2000;160:2185–2191.
136. Bach D, Rissanen A, Mendel CM, et al. Absence of cardiac valve dysfunction in obese patients treated with sibutramine. Obes Res 1999;7:363–369.
137. Heck A, Yanovski J, Calis J. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy 2000;20:270–279.
138. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999;281(3):235–242.
139. Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998;352:167–172.
140. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care 1998; 21(8):1288–1294.
141. Mittendorfer B, Ostlund RE Jr, Patterson BW, et al. Orlistat inhibits dietary cholesterol absorption. Obes Res 2001;9:599–604.
142. Anonymous. Physicians’ desk reference, 55th ed. Montvale, NJ: Medical Economics, 2001.
143. Munro J, MacCuish A, Wilson E, et al. Comparison of continuous and intermittent anoretic therapy in obesity. BMJ 1968;1:352–356.
144. Williams RA, Foulsham BM. Weight reduction in osteoarthritis using phentermine. Practitioner 1981;225:231–232.
145. Connolly H, Crary J, McGoon M, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337: 581–588.
146. Connolly H, McGoon M. Obesity drugs and the heart. Curr Probl Cardiol 1999;24:745–792.
147. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 335(9):609–616.
148. Wadden TA, Berkowitz R, Womble L, et al. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes Res 2000;8:431–437.
149. Bray GA. Contemporary diagnosis and management of obesity. Newton, PA: Handbooks in Healthcare, 1998.
150. Anderson JW, Greenway FL, Fujioka K, et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res 2002;10(7):633–641.
151. Gadde KM, Parker CB, Maner LG, et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res 2001;9(9):544–551.
152. Smith U, Axelsen M, Hellebö-Johanson E, et al. Topiramate, a novel antiepileptic drug reduces body weight and food intake in obesity [Abstract]. Obes Res 2000;8(suppl):10.
153. Teter CJ, Early JJ, Gibbs CM. Treatment of affective disorder and obesity with topiramate. Ann Pharmacother 2000;34(11):1262–1265.
154. Glauser T. Topiramate. Epilepsia 1999;40(suppl 5):71–80.
155. UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes mellitus (UKPDS 34). Lancet 1998;352: 854–865.
156. Astrup A, Breum L, Toubro S, et al. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet: a double blind trial. Int J Obes Rel Metab Disord 1992;16:269–277.
157. Toubro S, Astrup A, Breum L, et al. Safety and efficacy of long-term treatment with ephedrine, caffeine and an ephedrine/caffeine mixture. Int J Obes Rel Metab Disord 1993;17(suppl 1):69–72.
158. Daly P, Krieger D, Dulloo A, et al. Ephedrine, caffeine and aspirin: safety and efficacy for treatment of human obesity. Int J Obes Rel Metab Disord 1993;17(suppl 1):73–78.
159. Boozer CN, Nasser J, Heymsfield SB, et al. Efficacy of an herbal mixture of Ma Huang and Guarana for weight loss. Int J Obes 2001; 25:316–324.
160. Allison DB, Fontaine K, Heshka S, et al. Alternative treatments for weight loss: a critical review. Crit Rev Food Sci Nutr 2001;41:1–28.
161. Ferster C, Nurnberger J, Levitt E. The control of eating. J Math 1962;87–109.
162. Stuart R. Behavioral control of overeating. Behav Res Ther 1967;5: 357–365.
163. Mahoney M. Cognition and behavior modification. Cambridge, MA: Ballinger, 1974.
164. Mahoney M, Mahoney K. Permanent weight control. New York: Norton, 1976.
165. Meichenbaum D. Cognitive behavior modification. New York: Plenum, 1977.
166. Brownell KD, Marlatt G, Lichtenstein E, et al. Understanding and preventing relapse. Am Psychologist 1986;41:765–782.
167. Brownell KD, Rodin J. The weight maintenance survival guide. Dallas, TX: American Health, 1990.
168. Foreyt J, Goodrick G. Attributes of successful approaches to weight loss and control. Appl Prev Psychol 1994;3:209–215.
169. Stunkard AJ. An overview of current treatments for obesity. In: Wadden TA, Van Itallie TB, eds. Treatment of the severely obese patient. New York: Guilford, 1992:33–43.
170. Wadden TA, Foster GD. Behavioral assessment and treatment of markedly obese patients. In: Wadden TA, Van Itallie TB, eds. Treatment of the severely obese patient. New York: Guilford, 1992:290–330.
171. Klem ML, Wing RR, McGuire MT, et al. A descriptive study of individuals successful at long-term maintenance of substantial weight loss. Am J Clin Nutr 1997;66(2):239–246.
172. Wilson GT. Cognitive behavior therapy: paradigm shift or passing phase? In: Foreyt JP, ed. Cognitive behavior therapy. New York: Plenum, 2003:7–32.
173. Perri MG, McAdoo WG, Spevak PA, et al. Effect of a multicomponent maintenance program on long-term weight loss. J Consult Clin Psychol 1984;52(3):480–481.
174. Wadden TA, Sternberg JA, Letizia KA, et al. Treatment of obesity by very low calorie diet, behavior therapy, and their combination: a five-year perspective. Int J Obes 1989;13(suppl 2):39–46.
175. Perri MG, Shapiro RM, Ludwig WW, et al. Maintenance strategies for the treatment of obesity: an evaluation of relapse prevention training and posttreatment contact by mail and telephone. J Consult Clin Psychol 1984;52(3):404–413.
176. Baum JG, Clark HB, Sandler J. Preventing relapse in obesity through posttreatment maintenance systems: comparing the relative efficacy of two levels of therapist support. J Behav Med 1991;14(3): 287–302.
177. Perri MG, McAdoo WG, McAllister DA, et al. Effects of peer support and therapist contact on long-term weight loss. J Consult Clin Psychol 1987;55(4):615–617.
178. Gastrointestinal surgery for severe obesity: National Institutes of Health Consensus Development Conference Statement. Am J Clin Nutr 1992;55(suppl):615–619.
179. Flancbaum L. The doctor’s guide to weight loss surgery. West Hurley, NY: Fredonia Communications, 2001.
180. Belachew M, Monami B. Laparoscopic adjustable silicone gastric banding: technique and preliminary results. Obes Surg 1995;5:258.
181. Mason EE. Vertical banded gastroplasty for obesity. Arch Surg 1982;117(5):701–706.
182. Mason EE, Ito C. Gastric bypass in obesity. Surg Clin North Am 1967;47(6):1345–1351.
183. Scopinaro N, Gianetta E, Civalleri D, et al. Partial and total biliopancreatic bypass in the surgical treatment of obesity. Int J Obes 1981;5(4):421–429.
184. Scopinaro N, Gianetta E, Adami GF, et al. Biliopancreatic diversion for obesity at eighteen years. Surgery 1996;119:261–268.
185. Sugerman HJ, Kellum JM, Engle KM, et al. Gastric bypass for treating severe obesity. Am J Clin Nutr 1992;55(2 suppl):560–566.
186. Sjöström L, Larsson B, Backman L, et al. Swedish obese subjects (SOS): recruitment for an intervention study and a selected description of the obese state. Int J Obes 1992;16:465–479.
187. Sjöström CD, Lissner L, Wedel H, et al. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res 1999;7:477–484.
188. Sjöström C, Peltonen M, Wedel H, et al. Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension 2000;36(1):20–25.